Qualigen Therapeutics, Inc.
QLGN
$1.97
$0.073.68%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -72.28% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -72.28% |
Cost of Revenue | 59.58% | -84.48% | -152.39% | -127.70% | -113.33% |
Gross Profit | -59.58% | 84.48% | 152.39% | 127.70% | 117.82% |
SG&A Expenses | -2.42% | -30.98% | -46.09% | -51.22% | -38.75% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -35.39% | -52.20% | -46.22% | -37.57% | -33.40% |
Operating Income | 35.39% | 52.20% | 46.22% | 37.57% | 26.45% |
Income Before Tax | 39.93% | 50.66% | 42.82% | 31.78% | 20.05% |
Income Tax Expenses | 110.00% | 550.00% | -210.34% | -172.41% | -86.11% |
Earnings from Continuing Operations | 39.92% | 50.63% | 42.89% | 31.84% | 20.08% |
Earnings from Discontinued Operations | 69.79% | 89.39% | 97.78% | 87.37% | 91.86% |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 40.77% | 53.35% | 54.71% | 44.50% | 36.13% |
EBIT | 35.39% | 52.20% | 46.22% | 37.57% | 26.45% |
EBITDA | 59.99% | 51.43% | 45.43% | 37.33% | 26.69% |
EPS Basic | 83.89% | 74.56% | 69.64% | 55.56% | 49.09% |
Normalized Basic EPS | 81.95% | 72.96% | 65.07% | 48.18% | 39.35% |
EPS Diluted | 83.89% | 74.56% | 69.66% | 55.58% | 49.11% |
Normalized Diluted EPS | 81.95% | 72.96% | 65.07% | 48.18% | 39.35% |
Average Basic Shares Outstanding | 554.07% | 256.08% | 98.03% | 31.12% | 26.68% |
Average Diluted Shares Outstanding | 554.07% | 256.08% | 98.03% | 31.12% | 26.68% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |